Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2013

View Archived Issues

Novel aminoglycoside antibiotic shows anti-MRSA activity with reduced nephrotoxicity

CETP inhibitors for the treatment of atherosclerosis

Smallpox vaccine CJ-50300 safe in phase III trial

Novan compares activity of Nitricil compounds against Staphylococcus aureus

Acacia Pharma initiates phase III studies of APD-421 for PONV

Regado Biosciences begins phase III trial of pegnivacogin/anivamersen

PeptiDream licenses PDPS technology to Bristol-Myers Squibb

AGE receptors identified in human osteoarthritic cartilage

Agenus reports follow-on phase II data for brain cancer vaccine

Third review also recommends PreSERVE AMI study continuation

Repros Therapeutics reports Androxal study data

BioCryst awarded NIAID contract to combat Marburg virus hemorrhagic fever

Eslicarbazepine acetate meets primary endpoint in two phase III epilepsy studies

GW Pharmaceuticals begins phase I study of cannabinoid GWP-42006 for epilepsy

Profectus BioSciences begins phase I trial of HIV plasmid DNA vaccine

H3 Biomedicine and Selvita establish strategic collaboration in oncology

Compugen reports data on immune checkpoint protein CGEN-15049

Rottapharm patents novel orexin OX1 receptor antagonists

FORMA Therapeutics and Genentech disclose Nampt inhibitors

PIQUR Therapeutics plans phase I study of PQR-309

Takeda designs series of MetAP 2 inhibitors

Allergan synthesizes series of chemokine CCR2 receptor antagonists

ChemoCentryx regains rights to vercirnon from GlaxoSmithKline

Mitsubishi Tanabe Pharma acquires Medicago

CE mark granted to Abbott's FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...